- Home
- ALDF vs RIGL Comparison
ALDF vs RIGL Comparison
Compare ALDF & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDF
- RIGL
- Stock Information
- Founded
- ALDF 2024
- RIGL 1996
- Country
- ALDF United States
- RIGL United States
- Employees
- ALDF N/A
- RIGL N/A
- Industry
- ALDF
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ALDF
- RIGL Health Care
- Exchange
- ALDF NYSE
- RIGL Nasdaq
- Market Cap
- ALDF 301.4M
- RIGL 334.5M
- IPO Year
- ALDF 2024
- RIGL 2000
- Fundamental
- Price
- ALDF $10.43
- RIGL $18.17
- Analyst Decision
- ALDF
- RIGL Buy
- Analyst Count
- ALDF 0
- RIGL 5
- Target Price
- ALDF N/A
- RIGL $36.40
- AVG Volume (30 Days)
- ALDF 86.1K
- RIGL 196.8K
- Earning Date
- ALDF 01-01-0001
- RIGL 05-06-2025
- Dividend Yield
- ALDF N/A
- RIGL N/A
- EPS Growth
- ALDF N/A
- RIGL N/A
- EPS
- ALDF N/A
- RIGL 2.08
- Revenue
- ALDF N/A
- RIGL $203,077,000.00
- Revenue This Year
- ALDF N/A
- RIGL $12.53
- Revenue Next Year
- ALDF N/A
- RIGL $15.68
- P/E Ratio
- ALDF $99.65
- RIGL $8.82
- Revenue Growth
- ALDF N/A
- RIGL 70.16
- 52 Week Low
- ALDF $9.90
- RIGL $7.48
- 52 Week High
- ALDF $10.69
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- ALDF N/A
- RIGL 46.92
- Support Level
- ALDF N/A
- RIGL $17.65
- Resistance Level
- ALDF N/A
- RIGL $19.75
- Average True Range (ATR)
- ALDF 0.00
- RIGL 1.44
- MACD
- ALDF 0.00
- RIGL -0.02
- Stochastic Oscillator
- ALDF 0.00
- RIGL 15.69
About ALDF ALDEL FINL II INC
Aldel Financial II Inc is a Shell Company with various businesses.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.